Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma

Launched by IOMEDICO AG · Apr 5, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness of a medication called zanubrutinib for patients with certain types of blood cancers, including Waldenström's macroglobulinemia, chronic lymphocytic leukemia, marginal zone lymphoma, and follicular lymphoma. The main goal is to understand how well this treatment works in real-life settings, how it affects patients' quality of life, and how healthcare resources are used during treatment.

To participate, individuals need to be at least 18 years old and diagnosed with one of the specified conditions, with specific treatment history. For example, patients with marginal zone lymphoma must have received at least two prior treatments, and those with follicular lymphoma must have had three. Participants will be treated with zanubrutinib, either alone or in combination with another medication, and will provide consent to join the study. The trial is currently recruiting, so if you or someone you know meets these criteria, it might be an opportunity to consider.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Waldenström's macroglobulinemia (all treatment lines) OR
• • Chronic lymphocytic leukemia (all treatment lines) OR
• • Marginal zone lymphoma (≥2 treatment line and at least one anti-CD20 antibody-based previous therapy)
• • Follicular lymphoma (≥3 treatment line)
• • Signed and dated informed consent form
• • Treatment with zanubrutinib according to current SmPC for WM, CLL and MZL
• • Treatment with zanubrutinib + obinutuzumab for FL according to current SmPC
• • Treatment decision before inclusion into this non-interventional study
• • Age ≥18 years.
• Exclusion Criteria:
• • Contraindications according to SmPC for patients with WM, CLL, MZL or FL
• • Participation in an interventional clinical trial during zanubrutinib treatment.